REVIEW Rilpivirine(R 278474, TMC 278) is a type of anti-HIV medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). IC50 Value: Target: NNRTIs Rilpivirine(TMC278) is a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. NNRTIs work by binding to and blocking HIV reverse transcriptase, an HIV enzyme. This prevents HIV from replicating and lowers the amount of HIV in the blood. Rilpivirine does not cure HIV/AIDS. It is not known if rilpivirine reduces the risk of passing HIV to other people.
Gomes T, Juurlink DN, Mamdani MM.Comparative adherence to oxybutynin or tolterodine among older patients.Eur J Clin Pharmacol. 2012 Jan;68(1):97-9. Epub 2011 Jun 28.
Vingerhoets J, Rimsky L, Van Eygen V, Nijs S, Vanveggel S, Boven K, Picchio G.Preexisting mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virologic response.Antivir Ther. 2012 Sep 6.
Schafer JJ, Short WR.Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.Antivir Ther. 2012 Jul 25.
Singh K, Marchand B, Rai DK, Sharma B, Michailidis E, Ryan EM, Matzek KB, Leslie MD, Hagedorn AN, Li Z, Norden PR, Hachiya A, Parniak MA, Xu HT, Wainberg MA, Sarafianos SG.Biochemical Mechanism of HIV-1 Resistance to Rilpivirine.J Biol Chem. 2012 Sep 6. Guillemont, Jerome; Journal of Medicinal Chemistry 2005, V48(6), P2072-2079